Short answer
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results announced February 24, 2026.
Fulcrum Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced February 24, 2026
- Full financials in Exhibit 99.1: key figures not disclosed in this item text
- FULC is a clinical-stage biotech; results context hinges on pipeline progress and cash runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulcrum Therapeutics, Inc. 8-K filings
Get the next FULC 8-K as it lands
Follow FULC for push alerts, or ask the research agent what this filing means.